Gridai Technologies Corp. (GRDX) — 8-K Filings

8-K Filings (43)

• GridAI Technologies Corp. Files 8-K: Agreements, Officer Changes — Dec 23, 2025 Risk: medium
  On December 19, 2025, GridAI Technologies Corp. entered into a material definitive agreement. The company also reported the departure of directors or certain of
• GridAI Technologies Corp. Files 8-K with Key Corporate Updates — Dec 4, 2025 Risk: medium
  GridAI Technologies Corp. filed an 8-K on December 4, 2025, reporting several key events as of November 28, 2025. These include entering into a material definit
• Entero Therapeutics Files 8-K — Nov 6, 2025 Risk: low
  Entero Therapeutics, Inc. filed an 8-K on November 6, 2025, reporting an event on October 17, 2025. The filing is a current report under Section 13 or 15(d) of
• 8-K Filing — Oct 31, 2025
• Entero Therapeutics Enters Material Definitive Agreement — Oct 22, 2025 Risk: medium
  On October 17, 2025, Entero Therapeutics, Inc. entered into a material definitive agreement. This filing also indicates the creation of a direct financial oblig
• Entero Therapeutics Completes Acquisition, Discloses Equity Sales — Oct 6, 2025 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) announced on September 30, 2025, the completion of an acquisition. The filing also disclosed unr
• Entero Therapeutics Files 8-K: Agreements, Officer Changes, Financials — Sep 12, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on September 12, 2025, the entry into a material definitive agreement. The company also reported the departure of directors
• Entero Therapeutics Reports Agreement Termination & Officer Changes — Sep 9, 2025 Risk: medium
  Entero Therapeutics, Inc. filed an 8-K on September 9, 2025, reporting the termination of a material definitive agreement and changes in its board and officer c
• Entero Therapeutics Files 8-K on Security Holder Rights — Aug 15, 2025 Risk: medium
  Entero Therapeutics, Inc. filed an 8-K on August 15, 2025, reporting material modifications to security holder rights and other events as of August 14, 2025. Th
• Entero Therapeutics Files 8-K: Agreements, Equity Sales, Officer Changes — Aug 11, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on August 9, 2025, the entry into a material definitive agreement. The company also reported on unregistered sales of equity
• Entero Therapeutics Enters Material Definitive Agreement — Jul 16, 2025 Risk: medium
  On July 15, 2025, Entero Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as First Wave BioPharma, Inc., is incorpor
• Entero Therapeutics to Acquire 03 Life Sciences — Jul 8, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on July 3, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of 03 Life Scie
• Entero Therapeutics Files 8-K on Shareholder Vote Matters — Jul 2, 2025 Risk: low
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on July 2, 2025, reporting on a submission of matters to a vote of security holders
• Entero Therapeutics Files 8-K for Unspecified Event — Jun 30, 2025 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on June 30, 2025, reporting an "Other Event" that occurred on June 25, 2025. The fi
• Entero Therapeutics Files 8-K on Agreements and Shareholder Nominations — May 14, 2025 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on May 14, 2025, reporting on several key events. These include entering into a mat
• Entero Therapeutics Faces Delisting Concerns — Apr 14, 2025 Risk: high
  Entero Therapeutics, Inc. filed an 8-K on April 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The compan
• Entero Therapeutics Announces Material Agreement, Officer Changes — Mar 25, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on March 24, 2025, a material definitive agreement and changes in its board and officer composition. The company also disclo
• Entero Therapeutics Reports Delisting Notice & Officer Changes — Mar 7, 2025 Risk: high
  Entero Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting several key events as of March 3, 2025. These include entering into a material definitive agr
• Entero Therapeutics Announces Board and Compensation Changes — Feb 14, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on February 12, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes i
• Entero Therapeutics Files 8-K: Agreements, Obligations, and Leadership Changes — Feb 6, 2025 Risk: medium
  Entero Therapeutics, Inc. announced on January 31, 2025, the entry into a material definitive agreement and the creation of a direct financial obligation. The f
• Entero Therapeutics Faces Delisting Concerns — Jan 13, 2025 Risk: high
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on January 13, 2025, reporting a notice of delisting or failure to satisfy a contin
• Entero Therapeutics Reports Financial Obligation Event — Nov 27, 2024 Risk: medium
  On November 21, 2024, Entero Therapeutics, Inc. reported a triggering event related to accelerating or increasing a direct financial obligation. The company, fo
• Entero Therapeutics Enters Material Definitive Agreement — Nov 13, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on November 8, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as First Wave BioPhar
• Entero Therapeutics Faces Delisting Notice — Sep 11, 2024 Risk: high
  Entero Therapeutics, Inc. filed an 8-K on September 11, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The co
• Entero Therapeutics Files 8-K — Sep 10, 2024 Risk: low
  Entero Therapeutics, Inc. filed an 8-K on September 10, 2024, reporting on events that occurred on September 9, 2024. The filing includes information related to
• Entero Therapeutics to Acquire 03 Life Sciences — Sep 3, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on August 29, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of 03 Life S
• Entero Therapeutics Changes Auditors Amidst Accounting Disagreements — Aug 29, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on August 28, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered pub
• Entero Therapeutics Faces Delisting Concerns — Aug 23, 2024 Risk: high
  Entero Therapeutics, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company was former
• Entero Therapeutics Appoints New CEO, Dr. David J. Mazzo — Aug 22, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on August 16, 2024, the appointment of Dr. David J. Mazzo as Chief Executive Officer and a member of the Board of Directors.
• Entero Therapeutics Changes Auditors Amidst Disagreement — Aug 15, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on August 9, 2024, the departure of its independent registered public accounting firm, WithumSmith+Brown, PC. The company ha
• Entero Therapeutics Files 8-K: Delisting Risk, Exec Changes — Aug 7, 2024 Risk: high
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on August 7, 2024, reporting several key events. These include a triggering event f
• Entero Therapeutics Files 8-K — Jul 31, 2024 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) filed an 8-K on July 31, 2024, reporting a Regulation FD Disclosure and Financial Statements and
• Entero Therapeutics Appoints New CMO, Director — Jul 23, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on July 17, 2024, the appointment of Dr. Jonathan L. Cohen as Chief Medical Officer and the election of Ms. Sarah E. Empey t
• Entero Therapeutics Enters Material Definitive Agreement — Jul 11, 2024 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) entered into a material definitive agreement on July 10, 2024. The company, previously known as
• Entero Therapeutics Appoints New CMO, Director — Jun 20, 2024 Risk: medium
  Entero Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan L. Cohen as Chief Medical Officer and the election of Ms. Sarah E. Empey t
• Entero Therapeutics Appoints New Auditor, Dismisses BDO USA — Jun 5, 2024 Risk: medium
  Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) announced on June 1, 2024, a change in its certifying accountant. The company has dismissed BDO
• First Wave BioPharma Files 8-K with Corporate Updates — May 16, 2024 Risk: medium
  First Wave BioPharma, Inc. (formerly AzurRx BioPharma, Inc.) filed an 8-K on May 16, 2024, reporting events as of May 15, 2024. The filing indicates changes to
• First Wave BioPharma Files 8-K: Material Agreement & Equity Sales — May 13, 2024 Risk: medium
  First Wave BioPharma, Inc. announced on May 10, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equ
• First Wave BioPharma Faces Delisting Concerns — Mar 22, 2024 Risk: high
  First Wave BioPharma, Inc. filed an 8-K on March 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• First Wave BioPharma Files 8-K — Mar 18, 2024 Risk: low
  First Wave BioPharma, Inc. filed an 8-K on March 18, 2024, reporting other events and financial statements. The company, formerly AzurRx BioPharma, Inc., is inc
• First Wave BioPharma Secures $1.5M Private Placement, CMO Departs — Mar 14, 2024 Risk: medium
  First Wave BioPharma, Inc. announced on March 13, 2024, the closing of a definitive agreement for a private placement of approximately $1.5 million in gross pro
• First Wave BioPharma Files 8-K: Material Agreement & Equity Sales — Mar 5, 2024 Risk: medium
  On March 3, 2024, First Wave BioPharma, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The comp
• First Wave BioPharma Files 8-K for General Disclosure — Jan 4, 2024
  First Wave BioPharma, Inc. filed an 8-K on January 4, 2024, to disclose general information, specifically under Regulation FD Disclosure and Financial Statement

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX